Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
批准号:
8664791
负责人:
Robin Mark Warren
金额:
$13.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-21 至 2016-05-31
关键词:
AmikacinAntibiotic ResistanceAntibioticsAntitubercular AgentsBiological AssayCapromycinCaregiversCell Culture TechniquesClinicalCommunicable DiseasesComplexDNADNA SequenceDetectionDevelopmentDiagnosisDiagnosticDiseaseDrug Resistant TuberculosisEnsureEthambutolEvaluationExtreme drug resistant tuberculosisFoundationsFutureGeneticGenus MycobacteriumGrowthHealthHourInternationalKanamycinLaboratoriesMassachusettsMeasuresMethodsMolecularMorbidity - disease rateMutationMutation DetectionMycobacterium tuberculosisOfloxacinOutcomePatientsPerformancePharmaceutical PreparationsPreclinical Drug EvaluationPredispositionRegimenResearch InfrastructureResistanceRifampicin resistanceRifampinRiskSamplingSensitivity and SpecificityServicesSouth AfricaSpecimenSystemTechnologyTestingTimeTreatment outcomeTubeTuberculosisUniversitiesbaseclinical applicationclinically significantcost effectivedisease transmissionfollow-upimprovedisoniazidmortalitymycobacterialnovelnovel diagnosticspandemic diseasepoint-of-care diagnosticsprofessorrepositorystemtransmission processtuberculosis drugs
中文摘要
描述(由申请人提供):耐药结核病(TB)的诊断受到财政限制、基础设施不足、结核分枝杆菌生长速度缓慢以及抗生素耐药性遗传复杂性的阻碍。在全球诊断的结核病病例中,只有一小部分进行了药物敏感性筛查,因此,数十万结核病病例使用的是不适当的抗结核药物方案。其后果是灾难性的,包括高发病率和死亡率、耐药性增强以及疾病传播水平上升。广泛耐药结核病(XDR-TB)的出现促使国际社会呼吁更好地利用现有诊断方法并开发新的诊断方法。因此,世卫组织批准使用Line Probe法检测结核分枝杆菌复合体和异烟肼和/或利福平。这些新的检测方法通过使用快速分子方法在DNA水平上识别突变,而不是使用慢得多的细胞培养方法,建立了一种新的诊断范例。然而,Line Probe分析在技术上要求很高,需要使用先进的实验室来减少交叉污染的风险。为了避免这个问题,世卫组织最近批准了一种“包含PCR检测”,可以在2小时内检测到结核分枝杆菌复合体和利福平耐药性的存在。该系统的另一个优点是它可以在一些涂片阴性病例中检测到结核分枝杆菌复合体。但是,这种新的检测方法仅检测利福平耐药性,因此目前只能通过常规细胞培养方法提示后续药敏试验,再次延误诊断。本文描述的研究旨在通过向南非转让一项开创性技术来克服这些深刻的障碍,在南非,将使用Stellenbosch大学储存库中保存的具有良好特征的结核分枝杆菌样本以及来自国家卫生实验室服务的常规临床标本对该技术进行评估。这项技术被称为“开启/关闭探针和PrimeSafe”的后期pcr技术,由布兰迪斯大学(马萨诸塞州)的王教授发明,允许同时封闭试管检测对异烟肼、利福平、乙胺丁醇、氟喹诺酮类药物和氨基糖苷类药物以及引起疾病的分枝杆菌物种具有耐药性的突变。这项技术有可能彻底改变许多传染病药物敏感性的分子诊断领域,因为它可以快速、经济地确定突变谱,用于优化初始诊断时的药物治疗。因此,这项技术有可能降低发病率和死亡率,并有助于遏制全球结核病大流行。
英文摘要
DESCRIPTION (provided by applicant): The diagnosis of drug resistant tuberculosis (TB) is hampered by financial constraints, inadequate infrastructure, the slow growth rate of Mycobacterium tuberculosis, and the genetic complexity of antibiotic resistance. Only a fraction of tuberculosis cases diagnosed globally is screened for drug susceptibility, thus hundreds of thousands of TB cases are treated with inadequate regimens of anti-TB drugs. The consequences are catastrophic and include high levels of morbidity and mortality, amplification of resistance, and increasing levels of disease transmission. The emergence of the extensively drug resistant TB, XDR-TB, has prompted an international call for better use of current diagnostics and the development of novel diagnostics. Accordingly, the WHO approved the use of Line Probe assays for the detection of M. tuberculosis complex and isoniazid and/or rifampin. These novel assays established a new diagnostic paradigm by using rapid molecular methods that identified mutations at the DNA level, rather than far slower cell culture methods. However, Line Probe assays are technically demanding and require use of sophisticated laboratories to reduce the risk of cross contamination. To circumvent this problem the WHO recently approved a "contained PCR test" that detects the presence of M. tuberculosis complex and rifampin resistance within 2 hours. An added advantage of this system is that it can detect M. tuberculosis complex in some smear negative cases. But, this new test only measures rifampin resistance and thus currently only serves to prompt follow-up drug susceptibility testing by conventional cell culture methods, again delaying diagnosis. The study described here is aimed at overcoming these profound barriers by transferring a pioneering technology to South Africa, where it will be evaluated using well characterized M. tuberculosis samples held in the repository at Stellenbosch University, as well as, routine clinical specimens from the National Health Laboratory service. The technology, known as LATE-PCR with Lights-On/Lights-Off Probes and PrimeSafe", invented by Professor Wangh at Brandeis University (Massachusetts), allows for the simultaneous, closed-tube detection of mutations conferring resistance to isoniazid, rifampin, ethambutol, fluorquinolones and aminoglucosides, and mycobacterial species causing disease. This technology has the potential of revolutionizing the field of molecular diagnostics for drug susceptibility in many infectious diseases by rapidly and affordably defining a profile of mutations which can be used to optimize drug treatment at initial diagnosis. Thus this technology has the potential to reduce morbidity and mortality and to help stem the global TB pandemic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
-
批准号:8288372
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2012
-
负责人:Robin Mark Warren
-
依托单位:
Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
-
批准号:8495205
-
项目类别:
-
资助金额:$12.54万
-
财政年份:2012
-
负责人:Robin Mark Warren
-
依托单位:
Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
-
批准号:8850795
-
项目类别:
-
资助金额:$13.19万
-
财政年份:2012
-
负责人:Robin Mark Warren
-
依托单位:
海外基金